DEA’s Rescheduling of Cannabis will Boost Talarya Brands, which, Reports Record Q1 Growth
Talarya Brands, a pioneering leader in the cannabis industry, today highlighted record-breaking financial and operational performance following the recent Drug Enforcement Administration (DEA) decision to reclassify marijuana from a Schedule 1 to a Schedule 3 substance. This pivotal shift in the regulatory landscape opens up substantial growth opportunities for the company.
Talarya Brands reported a record 26% increase in revenue year over year in Q1, with gross margins expanding by 770 basis points quarter over quarter. The company achieved a new sales record with $5.65 million in Q1 and generated $297,000 in positive cash flow from operations in March alone. And in a rarity for a California operator, Talarya has been consistently EBITDA positive, underscoring …